Decitabine and Cedazuridine for Prostate Cancer
This study is evaluating whether a combination of drugs can improve the effectiveness of treatment for patients with castrate resistant prostate cancer.
See full descriptionAbout the trial for Prostate Cancer
Treatment Groups
This trial involves 2 different treatments. Decitabine And Cedazuridine is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
About The Treatment
Eligibility
This trial is for male patients aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Decitabine and Cedazuridine will improve 1 primary outcome and 1 secondary outcome in patients with Prostate Cancer. Measurement will happen over the course of Up to 30 days post-treatment.
Patient Q & A Section
What are the common side effects of decitabine and cedazuridine?
Results from a recent clinical trial showed that both agents can cause transient myelosuppression, but the incidence was not high enough to warrant dose modification. Myelosuppression appeared invariably reversible after discontinuation of treatment. Because severe neutropenia is associated with increased mortality, decitabine should be used carefully in elderly patients and cedazuridine must be used cautiously in women.
What causes prostate cancer?
Knowledge about the etiology of [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) is limited primarily because little research has been done. This lack of knowledge limits our ability to develop effective prevention strategies. Cancer Genetics Core investigators are combining their expertise in genetics, physiology and molecular biology to identify genetic predispositions and the best way to prevent prostate cancer.\nResearch in this area will lead to more effective treatment options and help reduce the number of unnecessary prostate biopsies and surgeries.
How serious can prostate cancer be?
Current guidelines recommend radical prostatectomy with intraoperative frozen section analysis for clinically organ confined localised prostate cancer. In accordance with these recommendations, low risk prostate cancers are treated surgically without the use of adjuvant therapy. However, it is clear that some prostate cancers do not fit into this category. They have either metastasized locally or systemically and therefore warrant more aggressive treatments.
What is the primary cause of prostate cancer?
Recent findings does not support an association between smoking and prostate cancer incidence. The higher prostate cancer incidence among the black cohort may be explained by earlier age at onset of smoking and longer duration of smoking. However, smoking was strongly associated with a lower age at first diagnosis of prostate cancer. Furthermore, our findings suggest that African Americans are more likely than whites to be diagnosed with prostate cancer late in life.
Have there been other clinical trials involving decitabine and cedazuridine?
Decitabine and cedazuridine are both active agents in determining prognosis in patients with advanced gastrointestinal stromal tumours. Data from a recent study suggests that further use of these agents in the treatment of GISTs should be explored in future trials.
What is prostate cancer?
An increasing proportion of men with PC are diagnosed at an earlier stage. This may reflect greater awareness of symptoms by clinicians. The exact cause remains unknown. Results from a recent clinical trial suggest that the increase in PC incidence can be attributed to changes in diagnostic practices rather than changes in exposure to carcinogens; however, further studies are needed to confirm our results and to identify other possible causes.
What are the signs of prostate cancer?
• The signs and symptoms of [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) vary according to the stage and grade of cancer, but can be broadly categorized into four groups: • The early signs and symptoms include lower urinary tract symptoms such as frequency, urgency, and urge incontinence; the late signs and symptoms are skeletal metastases, which may occur within 12 months after the initial pathology report; • The biochemical features of prostate cancer are listed below; • • The pathologic features are listed below.
Is decitabine and cedazuridine safe for people?
Decitabine and cedazuridine are well tolerated at the doses studied. These agents have significant activity against pediatric leukemia. Decitabine was also found to be active In a recent study with only mild side effects. Cedazuridine did not show any active anti-leukemia effects but it produced severe myelosuppression in most patients.
How many people get prostate cancer a year in the United States?
Breast cancer affects about 1,200,000 women and colon cancer affects about 700,000 women each year in the United States; however, prostate cancer affects only about 100,000 men during their lifetime. This means that less than 10% of all cancers are related to sex. It also means that more than 20 million men over the age of 50 years will be affected by prostate cancer at some time in their lives.
What are common treatments for prostate cancer?
Although many treatment options are available for prostate cancer, some treatment options can cause serious side effects. Physicians need to be aware of common treatment options for prostate cancer when counseling patients.
What does decitabine and cedazuridine usually treat?
In spite of its effectiveness as an anti-cancer agent, decitabine behaved like conventional chemotherapy in terms of toxicity, side effects and response rate. Cedazuridine was better tolerated but still less effective than decitabine. Decitabine had better efficacy when compared with cedazuridine for patients who were previously treated with bortezomib. This suggests that these drugs could be combined in the treatment of relapsed patients.